Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.

[1]  A. Cheng,et al.  Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma , 2010, British Journal of Cancer.

[2]  P. Galle,et al.  Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis , 2009, Journal of clinical gastroenterology.

[3]  S. Fan,et al.  Phase 2 open‐label study of single‐agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B–endemic Asian population , 2009, Cancer.

[4]  S. Paggi,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[5]  A. Goldhirsch,et al.  Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  X. Paoletti,et al.  Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Furuse,et al.  Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma , 2007, Cancer science.

[8]  R. Kerbel,et al.  Molecular and cellular biomarkers for angiogenesis in clinical oncology. , 2007, Drug discovery today.

[9]  Robert S. Kerbel,et al.  The multifaceted circulating endothelial cell in cancer: towards marker and target identification , 2006, Nature Reviews Cancer.

[10]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Kerbel,et al.  Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. , 2006, Cancer research.

[12]  A. Goldhirsch,et al.  Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  R. Kerbel,et al.  Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. , 2005, Blood.

[14]  A. Maraveyas,et al.  Can a rational design for metronomic chemotherapy dosing be devised? , 2005, British Journal of Cancer.

[15]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[16]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[17]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[18]  H. Schmoll.  Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. , 2003, Anti-cancer drugs.

[19]  H. Asakura,et al.  Improved survival with oral administration of enteric‐coated tegafur/uracil for advanced stage IV‐A hepatocellular carcinoma , 2001, Journal of gastroenterology and hepatology.

[20]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[21]  K. Wierzba,et al.  UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[23]  R. Makuch,et al.  Sample size requirements for evaluating a conservative therapy. , 1978, Cancer treatment reports.

[24]  Chiun Hsu,et al.  Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. , 2010, Contemporary clinical trials.

[25]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[26]  Wolfgang Vogel,et al.  Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. , 2009, The oncologist.

[27]  K. Wierzba,et al.  γ-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor , 2004, Angiogenesis.

[28]  K. Wierzba,et al.  gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. , 2001, Angiogenesis.

[29]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[30]  S. Baruchel,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. , 2000, The Journal of clinical investigation.

[31]  G. Peters,et al.  UFT: mechanism of drug action. , 2000, Oncology.

[32]  F. Cabanillas.  Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. , 2000, Oncology.

[33]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.